Examination of SARS-CoV-2 serological test results from multiple commercial and laboratory platforms with an in-house serum panel

Severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) is a novel human coronavirus that was identified in 2019. SARS-CoV-2 infection results in an acute, severe respiratory disease called coronavirus disease 2019 (COVID-19). The emergence and rapid spread of SARS-CoV-2 has led to a global public health crisis, which continues to affect populations across the globe. Real time reverse transcription polymerase chain reaction (rRT-PCR) is the reference standard test for COVID-19 diagnosis. Serological tests are valuable tools for serosurveillance programs and establishing correlates of protection from disease. This study evaluated the performance of one in-house enzyme linked immunosorbent assay (ELISA) utilizing the pre-fusion stabilized ectodomain of SARS-CoV-2 spike (S), two commercially available chemiluminescence assays Ortho VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack and Abbott SARS-CoV-2 IgG assay and one commercially available Surrogate Virus Neutralization Test (sVNT), GenScript USA Inc., cPass SARS-CoV-2 Neutralization Antibody Detection Kit for the detection of SARS-CoV-2 specific antibodies. Using a panel of rRT-PCR confirmed COVID-19 patients’ sera and a negative control group as a reference standard, all three immunoassays demonstrated high comparable positivity rates and low discordant rates. All three immunoassays were highly sensitive with estimated sensitivities ranging from 95.4%-96.6%. ROC curve analysis indicated that all three immunoassays had high diagnostic accuracies with area under the curve (AUC) values ranging from 0.9698-0.9807. High positive correlation was demonstrated among the conventional microneutralization test (MNT) titers and the sVNT inhibition percent values. Our study indicates that independent evaluations are necessary to optimize the overall utility and the interpretation of the results of serological tests. Overall, we demonstrate that all serological tests evaluated in this study are suitable for the detection of SARS-CoV-2 antibodies.

                                            [
  "009:20"
]
                                        

                                            {
  "fn": "CDC-INFO",
  "@type": "vcard:Contact",
  "hasEmail": "mailto:cdcinfo@cdc.gov"
}
                                        

                                            [
  {
    "@type": "dcat:Distribution",
    "mediaType": "text/csv",
    "downloadURL": "https://data.cdc.gov/api/views/hhvg-83jq/rows.csv?accessType=DOWNLOAD"
  },
  {
    "@type": "dcat:Distribution",
    "mediaType": "application/json",
    "downloadURL": "https://data.cdc.gov/api/views/hhvg-83jq/rows.json?accessType=DOWNLOAD"
  },
  {
    "@type": "dcat:Distribution",
    "mediaType": "application/rdf+xml",
    "downloadURL": "https://data.cdc.gov/api/views/hhvg-83jq/rows.rdf?accessType=DOWNLOAD"
  },
  {
    "@type": "dcat:Distribution",
    "mediaType": "application/xml",
    "downloadURL": "https://data.cdc.gov/api/views/hhvg-83jq/rows.xml?accessType=DOWNLOAD"
  }
]
                                        

                                            [
  "antibodies",
  "covid-19",
  "immunoassays",
  "neutralization assay",
  "sars-cov-2",
  "serological tests"
]
                                        

                                            [
  "009:026"
]
                                        

                                            {
  "name": "Centers for Disease Control and Prevention",
  "@type": "org:Organization"
}
                                        

                                            [
  "Coronavirus and Other Respiratory Viruses"
]